New drug cocktail aims to stop High-Risk myeloma from coming back
NCT ID NCT05776979
First seen Nov 19, 2025 · Last updated Jun 20, 2026 · Updated 30 times
Summary
This phase 2 trial is testing whether adding isatuximab to lenalidomide after a stem cell transplant can better control high-risk multiple myeloma. About 61 adults aged 18 to 72 will receive the drug combination. The main goal is to check safety and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
isatuximab and lenalidomide
What this could lead to
If it works, this combination could help keep high-risk multiple myeloma under control for longer after a stem cell transplant.
What could go wrong
This is a small, early-phase trial (61 people) focused on safety, so it may not prove the treatment works. Side effects from the drugs are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.